I
Overview
ImmunityBio develops immunotherapies to treat cancer and infectious diseases by boosting the body's immune system, using natural killer (NK) cell–based therapies and viral vector vaccines. Its treatments train or arm immune cells to recognize and attack cancer cells or infections, with some therapies advancing through clinical trials for safety and tolerability. The company differentiates itself by focusing on immune-system–enhancing approaches aimed at hard-to-treat cancers and infectious diseases. Its goal is to outsmart diseases by leveraging the body's natural defenses to offer new options for patients with limited treatment choices.
Work here?Claim your company
Simplify's take
What believers are saying
- Q3 2026 product revenue reached $48.7 million, up 53%, with $143.6 million year-to-date.
- October 2026 FDA expansion and November Israel approval widen ANKTIVA's addressable patient pool.
- November 9, 2026 QUILT-2.005 met its primary endpoint, supporting a year-end 2026 sBLA.
What critics are saying
- J&J's Inlexzo already booked nearly $200 million in 2026 sales, pressuring bladder-market share.
- ImmunityBio still loses heavily; Q3 2026 R&D hit $68.96 million against $48.74 million revenue.
- If the January 6, 2027 FDA decision disappoints, ANKTIVA's bladder-franchise thesis breaks.
What makes ImmunityBio unique
- ANKTIVA is the first FDA-approved IL-15 immunotherapy for bladder cancer, since April 2024.
- ImmunityBio won October 14, 2026 papillary-only NMIBC expansion without a new randomized phase 3 trial.
- Its Cancer BioShield platform combines NK cells, T cells, and memory T cells across cancers.
Help us improve and share your feedback! Did you find this helpful?